Chemotherapy of oligodendroglial tumours: Current developments

FORUM - Trends in Experimental and Clinical Medicine

Volumn 10, Issue 2, 2000, Pages 108-118

  van den Bent, M J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anaplastic; Chemotherapy; Low grade; Oligoastrocytoma; Oligodendroglioma; PCV

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; ETOPOSIDE; LOMUSTINE; PACLITAXEL; PROCARBAZINE; VINCRISTINE;

ANAPLASTIC CARCINOMA; ASTROCYTOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME 19Q; CHROMOSOME 1P; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; OLIGODENDROGLIOMA; POSTOPERATIVE PERIOD; QUALITY OF LIFE; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; EVALUATION STUDIES; HUMANS; LOMUSTINE; MAGNETIC RESONANCE IMAGING; NEOPLASM RECURRENCE, LOCAL; OLIGODENDROGLIOMA; PROCARBAZINE; TREATMENT OUTCOME; VINCRISTINE;

EID: 0033942479     PISSN: 11218142     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Oligodendrogliomas of the brain
2. Succesful chemotherapy for recurrent oligodendroglioma
3. Chemotherapy for oligodendroglioma
4. Response rate and prognostic factors of recurrent oligodendroglioma treated with PCV chemotherapy
5. Chemotherapy for anaplastic oligodendroglioma
6. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults
7. Pathology and Genetics. Tumours of the nervous system. Lyon, International agency for research on cancer
8. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype
9. Oligodendroglioma: Incidence and biological behavior in a defined population
10. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas
11. Prognostic factors in oligodendroglioma
12. Oligodendroglioma: A comparison of two grading systems
13. Oligodendrogliomas: The Mayo Clinic experience
14. Grading of oligodendrogliomas
15. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas
16. Oligodendroglioma: The Rotterdam-Dijkzigt experience
17. Cerebral oligodendroglioma: Prognostic factors and life history
18. Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria
19. Clinicopathologic correlations in the oligodendroglioma
20. The role of postoperative irradiation in the treatment of oligodendroglioma
21. The prognostic significance of K1-67 labeling indices for oligodendrogliomas
22. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis
23. Oligoastrocytomas: A clinicopathological study of 52 cases
24. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
25. Molecular genetic evidence for subtypes of oligoastrocytomas
26. Allelic loss of chromosome 1p predicts long term progression free survival after radiotherapy in patients with oligodendroglioma
27. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
28. A clinicopathological study of 323 patients with oligodendrogliomas
29. Intracranial oligodendrogliomas: Imaging findings in 35 untreated cases
30. Oligodendroglioma. An analysis of the value of radiation therapy
31. Oligodendroglioma. The Princess Margaret Hospital experience (1958-1984)
32. Oligodendroglioma: An analysis of 42 cases
33. Treatment of oligodendrogliomas with or without postoperative irradiation
34. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: A report of radiation therapy oncology group 83-02
35. Mixed oligoastrocytomas: A survival and prognostic factor analysis
36. Supratentorial low-grade glioma in adults: An analysis of prognostic factors and the timing of radiation
37. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization
38. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p
39. Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas
40. Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas
41. The treatment of anaplastic oligodendrogliomas and mixed gliomas
42. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas
43. Role of chemotherapy in oligodendroglial tumors: A review of the experience at the University of Torino
44. Low-grade oligodendroglioma responds to chemotherapy
45. Differential response of recurrent oligodendrogliomas vs astrocytomas to intravenous (IV) melphalan
46. High-dose thiotepa with autologous bone marrow rescue in recurrent malignant oligodendroglioma
47. The treatment of oligodendrogliomas and mixed oligodendroglioma- astrocytomas with PCV chemotherapy
48. Response criteria for phase II studies of supratentorial malignant glioma
49. Chemotherapy for lowgrade oligodendrogliomas?
50. Low-grade oligodendroglioma responds to chemotherapy
51. Chemotherapy with PCV for low grade nonenhancing oligodendrogliomas and oligoastrocytomas
52. Salvage chemotherapy for oligodendroglioma
53. Salvage chemotherapy with taxol for recurrent oligodendrogliomas
54. Aggressive oligodendroglioma: A chemosensitive tumor
55. Physiological characterization of malignant oligodendrogliomas responding to PCV chemotherapy
56. Oligodendrogliomas: CT measurement of transcapillary permeability and response to vincristine chemotherapy
57. A critique of the role of the blood brain barrier in the chemotherapy of human brain tumors
58. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylni-trosourea: A southwest oncology group study
59. 6 methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage
60. 6-methylguanine
61. 6-methylguanine-DNA methyltransferase activity in adult gliomas: Relation to patient and tumor characteristics
62. Immunohistochemical staining for alkyltransferase does not predict response to PCV chemotherapy in oligodendroglial tumors
63. 6-alkylguanine-DNA alkyltransferase and response to temodal in newly diagnosed malignant glioma
64. 6-alkylguanine-DNA- alkyltransferase of human tumour xenografts.
65. Immediate postoperative radiotherapy in low grade glioma improves progression free survival, but not overall survival: Preliminary results of an EORTC/MRC randomized phase III study
66. Cognitive functions and quality of life in patients with low-grade gliomas: The impact of radiotherapy